Amarin Corporation plc (Nasdaq: AMRN) to Ring The Nasdaq Stock Market Opening Bell
June 12 2017 - 10:00AM
What:Amarin Corporation plc (Nasdaq:AMRN), a
biopharmaceutical company focused on the commercialization and
development of therapeutics to improve cardiovascular health, will
visit the Nasdaq MarketSite in Times Square.
In honor of the occasion, John Thero, Chief Executive
Officer, will ring the Opening Bell.
Where:Nasdaq MarketSite – 4 Times Square – 43rd
& Broadway – Broadcast Studio
When:Tuesday, June 13, 2017 – 9:15 a.m. to 9:30
a.m. ET
Amarin Media Contact:Ovidio TorresOffice: (312)
329-3911Cell: (917) 991-3399ovidio.torres@finnpartners.com
Nasdaq MarketSite:Emily Pan(646)
441-5120emily.pan@nasdaq.com
Feed Information:Fiber Line (Encompass
Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:For multimedia features such as
exclusive content, photo postings, status updates and video of bell
ceremonies, please visit our Facebook
page:http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our
Instagram page:http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our
YouTube page:http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter
page:http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our
Tumblr page:http://nasdaq.tumblr.com/
Webcast: A live stream of the Nasdaq Opening
Bell will be available at: https://new.livestream.com/nasdaq/live
or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of
the Market Open, please go to
http://business.nasdaq.com/discover/market-bell-ceremonies and
click on the market open of your choice.
About AmarinAmarin Corporation plc is a
biopharmaceutical company focused on the commercialization and
development of therapeutics to improve cardiovascular health.
Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits
of polyunsaturated fatty acids. Amarin's clinical program
includes a commitment to an ongoing outcomes study. Vascepa®
(icosapent ethyl), Amarin's first FDA approved product, is a
highly-pure, omega-3 fatty acid product available by
prescription. For more information about Vascepa
visit www.vascepa.com. For more information about Amarin
visit www.amarincorp.com.
About NasdaqNasdaq (Nasdaq:NDAQ) is a leading
global provider of trading, clearing, exchange technology, listing,
information and public company services. Through its diverse
portfolio of solutions, Nasdaq enables customers to plan, optimize
and execute their business vision with confidence, using proven
technologies that provide transparency and insight for navigating
today's global capital markets. As the creator of the world's first
electronic stock market, its technology powers more than 89
marketplaces in 50 countries, and 1 in 10 of the world's securities
transactions. Nasdaq is home to 3,800 total listings with a market
value of $11 trillion. To learn more, visit:
http://business.nasdaq.com.
-NDAQA-
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Sep 2023 to Sep 2024